Literature DB >> 33603757

Extracellular Vesicles as Inflammatory Drivers in NAFLD.

Akshatha N Srinivas1, Diwakar Suresh1, Prasanna K Santhekadur1, Deepak Suvarna2, Divya P Kumar1.   

Abstract

Non-alcoholic fatty liver disease (NAFLD) is a highly prevalent chronic liver disease in most parts of the world affecting one-third of the western population and a growing cause for end-stage liver diseases such as hepatocellular carcinoma (HCC). Majorly driven by obesity and diabetes mellitus, NAFLD is more of a multifactorial disease affected by extra-hepatic organ crosstalk. Non-alcoholic fatty liver (NAFL) progressed to non-alcoholic steatohepatitis (NASH) predisposes multiple complications such as fibrosis, cirrhosis, and HCC. Although the complete pathogenic mechanisms of this disease are not understood, inflammation is considered as a key driver to the onset of NASH. Lipotoxicity, inflammatory cytokines, chemokines, and intestinal dysbiosis trigger both hepatic and systemic inflammatory cascades simultaneously activating immune responses. Over a few years, extracellular vesicles studied extensively concerning the pathobiology of NAFLD indicated it as a key modulator in the setting of immune-mediated inflammation. Exosomes and microvesicles, the two main types of extracellular vesicles are secreted by an array of most mammalian cells, which are involved mainly in cell-cell communication that are unique to cell type. Various bioactive cargoes containing extracellular vesicles derived from both hepatic and extrahepatic milieu showed critical implications in driving steatosis to NASH reaffirming inflammation as the primary contributor to the whole process. In this mini-review, we provide brief insights into the inflammatory mediators of NASH with special emphasis on extracellular vesicles that acts as drivers of inflammation in NAFLD.
Copyright © 2021 Srinivas, Suresh, Santhekadur, Suvarna and Kumar.

Entities:  

Keywords:  cytokines; exosomes; immune system; inflammation; microvesicles; nonalcoholic fatty liver disease

Year:  2021        PMID: 33603757      PMCID: PMC7884478          DOI: 10.3389/fimmu.2020.627424

Source DB:  PubMed          Journal:  Front Immunol        ISSN: 1664-3224            Impact factor:   7.561


  97 in total

1.  Hepatocyte mitochondrial DNA drives nonalcoholic steatohepatitis by activation of TLR9.

Authors:  Irma Garcia-Martinez; Nicola Santoro; Yonglin Chen; Rafaz Hoque; Xinshou Ouyang; Sonia Caprio; Mark J Shlomchik; Robert Lee Coffman; Albert Candia; Wajahat Zafar Mehal
Journal:  J Clin Invest       Date:  2016-01-25       Impact factor: 14.808

Review 2.  The ESCRT machinery in endosomal sorting of ubiquitylated membrane proteins.

Authors:  Camilla Raiborg; Harald Stenmark
Journal:  Nature       Date:  2009-03-26       Impact factor: 49.962

3.  Lipid-Induced Signaling Causes Release of Inflammatory Extracellular Vesicles From Hepatocytes.

Authors:  Petra Hirsova; Samar H Ibrahim; Anuradha Krishnan; Vikas K Verma; Steven F Bronk; Nathan W Werneburg; Michael R Charlton; Vijay H Shah; Harmeet Malhi; Gregory J Gores
Journal:  Gastroenterology       Date:  2016-01-05       Impact factor: 22.682

4.  Disruption of tumor necrosis factor alpha receptor 1 signaling accelerates NAFLD progression in mice upon a high-fat diet.

Authors:  Flavia Lambertucci; Ainelén Arboatti; María Guillermina Sedlmeier; Omar Motiño; María de Luján Alvarez; María Paula Ceballos; Silvina R Villar; Eduardo Roggero; Juan A Monti; Gerardo Pisani; Ariel D Quiroga; Paloma Martín-Sanz; Cristina Ester Carnovale; Daniel Eleazar Francés; María Teresa Ronco
Journal:  J Nutr Biochem       Date:  2018-05-02       Impact factor: 6.048

5.  Activation and dysregulation of the unfolded protein response in nonalcoholic fatty liver disease.

Authors:  Puneet Puri; Faridoddin Mirshahi; Onpan Cheung; Ramesh Natarajan; James W Maher; John M Kellum; Arun J Sanyal
Journal:  Gastroenterology       Date:  2007-10-26       Impact factor: 22.682

6.  Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity.

Authors:  Jorge Henao-Mejia; Eran Elinav; Chengcheng Jin; Liming Hao; Wajahat Z Mehal; Till Strowig; Christoph A Thaiss; Andrew L Kau; Stephanie C Eisenbarth; Michael J Jurczak; Joao-Paulo Camporez; Gerald I Shulman; Jeffrey I Gordon; Hal M Hoffman; Richard A Flavell
Journal:  Nature       Date:  2012-02-01       Impact factor: 49.962

Review 7.  Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease.

Authors:  Chris Estes; Homie Razavi; Rohit Loomba; Zobair Younossi; Arun J Sanyal
Journal:  Hepatology       Date:  2017-12-01       Impact factor: 17.425

Review 8.  Gut-Liver Axis, Gut Microbiota, and Its Modulation in the Management of Liver Diseases: A Review of the Literature.

Authors:  Ivana Milosevic; Ankica Vujovic; Aleksandra Barac; Marina Djelic; Milos Korac; Aleksandra Radovanovic Spurnic; Ivana Gmizic; Olja Stevanovic; Vladimir Djordjevic; Nebojsa Lekic; Edda Russo; Amedeo Amedei
Journal:  Int J Mol Sci       Date:  2019-01-17       Impact factor: 5.923

9.  Extracellular vesicles in liver disease and beyond.

Authors:  Laura Morán; Francisco Javier Cubero
Journal:  World J Gastroenterol       Date:  2018-10-28       Impact factor: 5.742

Review 10.  New Aspects of Lipotoxicity in Nonalcoholic Steatohepatitis.

Authors:  Nahum Mendez-Sanchez; Vania Cesar Cruz-Ramon; Oscar Lenin Ramirez-Perez; Jessica P Hwang; Beatriz Barranco-Fragoso; Jaqueline Cordova-Gallardo
Journal:  Int J Mol Sci       Date:  2018-07-13       Impact factor: 5.923

View more
  15 in total

Review 1.  Pathological Contribution of Extracellular Vesicles and Their MicroRNAs to Progression of Chronic Liver Disease.

Authors:  Chanbin Lee; Jinsol Han; Youngmi Jung
Journal:  Biology (Basel)       Date:  2022-04-21

2.  Analysis of the Sphingolipidome in NAFLD.

Authors:  David Montefusco; Johana Lambert; Andrea Anderson; Jeremy Allegood; L Ashley Cowart
Journal:  Methods Mol Biol       Date:  2022

3.  Enlarged extracellular vesicles are a negative prognostic factor in patients undergoing TACE for primary or secondary liver cancer-a case series.

Authors:  David Schöler; Mirco Castoldi; Markus S Jördens; Max Schulze-Hagen; Christiane Kuhl; Verena Keitel; Tom Luedde; Christoph Roderburg; Sven H Loosen
Journal:  PLoS One       Date:  2021-08-18       Impact factor: 3.240

Review 4.  Extracellular Vesicles in Non-alcoholic Fatty Liver Disease and Alcoholic Liver Disease.

Authors:  Dongqing Wu; Huaqing Zhu; Hua Wang
Journal:  Front Physiol       Date:  2021-07-14       Impact factor: 4.566

5.  Concerted regulation of non-alcoholic fatty liver disease progression by microRNAs in apolipoprotein E-deficient mice.

Authors:  Andrea R López-Pastor; Jorge Infante-Menéndez; Tamara González-Illanes; Paula González-López; Águeda González-Rodríguez; Carmelo García-Monzón; Melina Vega de Céniga; Leticia Esparza; Almudena Gómez-Hernández; Óscar Escribano
Journal:  Dis Model Mech       Date:  2021-12-24       Impact factor: 5.758

Review 6.  Analysis of Common Pathways and Markers From Non-Alcoholic Fatty Liver Disease to Immune-Mediated Diseases.

Authors:  Rocío Gallego-Durán; Rocío Montero-Vallejo; Douglas Maya-Miles; Ana Lucena; Franz Martin; Javier Ampuero; Manuel Romero-Gómez
Journal:  Front Immunol       Date:  2021-11-24       Impact factor: 7.561

Review 7.  Scramblases as Regulators of Proteolytic ADAM Function.

Authors:  Karina Reiss; Sinje Leitzke; Jana Seidel; Maria Sperrhacke; Sucharit Bhakdi
Journal:  Membranes (Basel)       Date:  2022-02-04

Review 8.  Circulating cell-specific extracellular vesicles as biomarkers for the diagnosis and monitoring of chronic liver diseases.

Authors:  Lauren A Newman; Kate Muller; Andrew Rowland
Journal:  Cell Mol Life Sci       Date:  2022-04-10       Impact factor: 9.261

Review 9.  Current and Potential Therapies Targeting Inflammation in NASH.

Authors:  Somaya Albhaisi; Mazen Noureddin
Journal:  Front Endocrinol (Lausanne)       Date:  2021-12-03       Impact factor: 5.555

Review 10.  Pathophysiological Mechanisms in Non-Alcoholic Fatty Liver Disease: From Drivers to Targets.

Authors:  Alvaro Santos-Laso; María Gutiérrez-Larrañaga; Marta Alonso-Peña; Juan M Medina; Paula Iruzubieta; María Teresa Arias-Loste; Marcos López-Hoyos; Javier Crespo
Journal:  Biomedicines       Date:  2021-12-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.